



22 December 2008

AVEXA LIMITED BROADCAST

AVEXA LIMITED (AVX) provides the opportunity to listen to an audio broadcast with Dr Julian Chick, Avexa CEO and Justus Homburg, Progen Pharmaceuticals Limited CEO, in a presentation titled "Merger of Avexa and Progen Presentation."

To listen, simply click on the link below:

Website link: <http://www.investorcalendar.com/IC/CEPage.asp?ID=139232>

About Avexa

Avexa Limited is a Melbourne-based biotechnology company with a focus on discovery, development and commercialisation of small molecules for the treatment of infectious diseases. Avexa has dedicated resources and funding for key projects including its HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections. The Company's lead program is apricitabine (ATC), an anti-HIV drug which has successfully completed the 48 week dosing of its Phase IIb trial and is currently in Phase III trials worldwide. www.avexa.com.au

About Progen

Progen Pharmaceuticals Limited is a globally focused biotechnology company committed to the discovery, development and commercialization of small molecule pharmaceuticals primarily for the treatment of cancer. Progen has built a focus and strength in anti-cancer drug discovery and development. Progen targets the multiple mechanisms of cancer across its three technology platforms, angiogenesis, epigenetics and cell proliferation. Progen has operations in Australia and the United States of America. www.progen.com.au

For more information:

Avexa
Dr. Julian Chick
Chief Executive Officer
+61 3 9208 4300

Progen
T Justus Homburg
Chief Executive Officer
+61 7 3842 3333

AU: Investor Relations
Sabrina Antoniou
Blueprint Life Science Group
+ 61 2 9519 5537

US: Investor Relations
Remy Bernarda
Blueprint Life Science Group
+ 1 415 375 3340 x2022